ArriVent Biopharmaceuticals is a clinical-stage biopharmaceutical company developing differentiated oncology medicines for cancer treatment, with a focus on non-small cell lung cancer patients with EGFR mutations. The company's lead asset, firmonertinib, is an investigational tyrosine kinase inhibitor targeting uncommon EGFR mutations, particularly exon 20 insertion and PACC mutations, which are largely underserved by existing therapies. ArriVent generates revenue through milestone payments and royalties from licensing agreements with global partners, while advancing a pipeline of antibody-drug conjugates through strategic collaborations, and outsources manufacturing to contract manufacturers, primarily in China.